Secondly, we conducted a comprehensive analysis of the molecular mechanisms of SD using network pharmacology, identifying key targets such as ANXA1, SOD2, HMOX1, MMP2, and XRCC6 that have not been previously reported in the context of NPC. This evidence concerns the gene ANXA1 and nasopharyngeal carcinoma.